Product news from 11/18/05 News Brief

Share this article:

The FDA approved Roche and Genentech's Tarceva (erlotinib) for a new indication as a treatment for patients with advanced pancreatic cancer. Tarceva has previously been approved by the FDA as a treatment for lung cancer.

Reliant Pharmaceuticals announced the FDA has approved its Supplemental New Drug Application for a new dosing regimen and label change for the fenofibrate therapy Antara (fenofibrate capsules) 43 mg and 130 mg. The new regimen enables patients to take Antara 130 mg capsules with or without food, increasing convenience for the 15% of adults in the U.S. with elevated triglycerides.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...